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Abstract - Several studies have shown a heightened 
inflammatory state in frail older adults, marked by high 
serum levels of interleukin-6 and C-reactive protein and 
an increased number of circulating leukocytes. Activation 
of monocytes and macrophages, marked by increased 
levels of neopterin, may contribute to chronic 
inflammation in the frail older adult. However, the 
reduced mononuclear cell response to lipopolysaccharide 
in vitro suggests the existence of defective activation 
pathways within the innate immune system possibly due 
to desensitization. Conversely, the expansion of CD8
+
 T 
cells, and specifically those expressing the CCR5 
chemokine receptor, above and beyond the levels 
observed in senescence, points to the involvement of 
adaptive immune pathways. In line with these 
observations, frail older adults exhibit a reduced antibody 
response to pneumococcal and influenza vaccines. 
Collectively, these observations support the existence of a 
dysregulated immune system in frail older adults and 
highlight the need for strategies to improve its function. 
 
Abbreviations - AIDS, acquired immunodeficiency 
syndrome; CCL, CC-chemokine receptor ligand; CCR, 
CC-chemokine receptor; CHS, Cardiovascular Health 
Study; CMV, cytomegalovirus; GTP, guanosine 
trisphosphate; HAART, highly active anti-retroviral 
therapy; HIV, human immunodeficiency virus; IDO, 
indoleamine-pyrrole 2,3-dioxygenase; IL, interleukin; 
IFN, interferon; MACS, Multicenter AIDS Cohort Study; 
NH2PPP, dihydro-neopterin trisphosphate; Tc, T 
cytotoxic; TCR, T-cell receptor; TEMRA, T effector 
memory cells re-expressing CD45RA; Th, T helper; 
TNF, tumor necrosis factor; WHAS, Women’s Health 
and Aging Study  
Aging is currently viewed as an active process, 
in which a number of factors concur to the progressive 
disruption of homeostasis in multiple physiologic 
systems, ultimately resulting in the development of age-
related diseases.  The aging of the immune system is 
associated with a decline in immunity against infections 
and a departure from the finely-tuned balance between 
physiologically beneficial, protective inflammation and 
inappropriate, undesirable inflammation. Among the 
factors involved in this process are a number of cytokines 
and mediators produced by cells of the immune system, 
most prominently interleukin (IL)-6 and tumor necrosis 
factor (TNF)-α. These are produced by cells of both the 
innate and adaptive axes of the immune system and 
repeatedly can be accounted for the chronic inflammatory 
changes underlying a diverse host of clinical 
manifestations in the aged individual, such as 
cardiovascular disease, autoimmune disease, 
osteoarthritis, cancer, dementia, and a few others [9]. 
While these changes may suggest a hyperactive, 
uncontrolled state of the aging immune system, they 
ultimately originate from a progressive immune defect 
[24]. 
  
T-cell senescence and the aging immune system  
The immune system can be targeted by several 
environmental insults, including radiations, chemicals, 
pathogens, and pharmacologic or biologic agents. 
Lymphocyte numbers can be rapidly and greatly reduced 
in response to exposure to immunosuppressive agents. 
Under physiologic conditions, these can be restored via 
the homeostatic expansion of surviving clones and the 
new generation of naïve clones from lymphopoietic 
tissues, namely the thymus and the bone marrow [29]. 
However, while homeostatic proliferation constitutes a 
positive selective pressure for clones responsive to 
persisting antigens, only active lymphopoiesis can ensure 
the reconstitution of a comprehensive repertoire of 
antigen specificities [18]. With advancing age, the 
contribution of lymphopoiesis becomes less prominent. It 
is well known that the thymus, the gland in which T cells 
develop and mature, undergoes involution throughout 
most of adult life. Thymic atrophy and, consequently, the 
dramatically reduced numbers of thymic emigrants in 
chronologic aging, are thought to be the primary reason 
for the progressive contraction of the naïve T-cell fraction 
and the relative expansion of the memory subset [24].  
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As a consequence of a failing reservoir of newly 
generated T cells, the aging immune system is 
characterized by a reduced level of diversity [31]. In this 
context, pre-existing clones reactive to less prevalent, 
occasional antigens will gradually be competed out and 
supplanted by clones expanding in response to such 
persisting antigens as cytomegalovirus (CMV) [1]. 




 clones account for the 
functional diversity of the T-cell receptor (TCR) 
repertoire in the healthy adult memory T-cell population, 
these can be reduced by up to 2 orders of magnitude in 
the senescent immune system [17,22]. This reduction in 
TCR repertoire diversity likely contributes to the reduced 
response to vaccines and the overall increased 
susceptibility to infections and tumors in older age. On 
the other hand, the relative prevalence of clones 
responsive to self antigens and chronic pathogens 
increases dramatically. For instance, clones specific for 
certain CMV antigens, e.g. pp65, may account for as 
much as 25% of the total CD8
+
 T-cell population in 
seropositive older adults [19]. However, sustained clonal 
expansion of these cells leads to their progressive 
senescence and exhaustion, which is accompanied by 
unique phenotypic and functional traits that have been 
extensively characterized in the CD8
+
 subset over the 
past few years. Indeed, it has been shown that persistent 
CMV infection is associated with a higher fraction of 
these terminally differentiated, senescent CD8
+
 T cells, 
typically referred to as TEMRA, or T effector memory cells 
re-expressing the naïve marker CD45RA [11]. Besides 
the CD45RA reversion, these cells also exhibit markedly 
reduced levels of the lymph node homing receptors 
CD62L and CCR7, and of the costimulatory receptors 
CD27 and CD28 [2,10]. The cells exhibit other signs of 
senescence, including shortened telomeres and a low 
proliferative response to mitogens, yet they are 
remarkably resistant to apoptosis, express higher levels of 
cytotoxicity effectors, e.g. granzyme B and perforin, and 
exhibit a raised level of activation at baseline possibly 
responsible for the increased serum levels of interferon 
(IFN)-γ commonly documented in older age [2,9,10,24]. 
 
A chronic immune burden in the development of 
frailty 
The immune changes that occur in the aging host have 
been likened to those occurring in human 
immunodeficiency virus (HIV)-infected patients prior to 
the introduction of highly active anti-retroviral therapy 
(HAART) [10]. Acquired immunodeficiency syndrome 
(AIDS) is characterized by a low naïve to memory ratio 
and a reduced T-cell repertoire as the result of reduced 
thymic function. While not directly affected by the 
primary infectious agent, CD8
+
 T cells undergo, in 
response to the sustained antigenic burden from HIV as 
well as other pathogens, e.g. CMV, a premature 
senescence process with expansion of CD28
-
 effector 
memory clones, heightened IFN-γ and TNF-α production 
and chronic inflammatory changes mediated by a host of 
innate immunity cytokines such as IL-6 [5]. Interestingly, 
in middle-aged patients enrolled in the Multicenter AIDS 
Cohort Study (MACS) prior to the HAART era an 
association was found between the degree of CD4
+
 T-cell 
depletion and a clinical picture virtually indistinguishable 
from that of frailty of older age [12]. Frailty was in that 
study defined by the coexistence of at least three of the 
five criteria defined by Fried and collaborators in the 
Cardiovascular Health Study (CHS) and subsequently 
validated in the Women’s Health and Aging Studies 
(WHAS): namely, weight loss, weakened handgrip, 
exhaustion, reduced gait speed, and reduced activity 
[3,14]. By adoption of these criteria the prevalence of this 
condition in older people not affected by other conditions 
has been estimated to range from 4% to 12% in different 
populations and age groups [13]. 
The pathogenesis of frailty of older age is 
postulated to involve multiple physiologic systems, 
including the immune system [15,28]. Data from the CHS 
showed that frail older adults, compared with non-frail 
ones, have elevated levels of C-reactive protein, even 
after excluding individuals with cardiovascular disease 
and diabetes and adjusting for age, sex, and race [26]. 
Clinical evidence from the MACS as well as studies of 
patients with systemic autoimmune conditions, together 
with the appreciation of consistent immune and 
inflammatory changes, lend support to the idea that 
sustained exposure to a persistent antigen(s), either 
infectious or autologous, might play a critical role as 
either a causative or precipitating factor [12,16]. Along 
this line, an association between frailty status, plasma IL-
6 concentrations, and CMV seropositivity was found in a 
recent collaborative study by our group [27]. The study, 
involving 635 participants from the WHAS cohort in 
1992 and 2002 (WHAS I and II), identified distinct levels 
of risk relationship between serum anti-CMV antibody 
(IgG) concentration and prevalent frailty, across groups 
of subjects categorized according to tertiles of plasma IL-
6 concentrations. That is, the higher the plasma IL-6 
concentration, the steeper the curve of the relationship 
between anti-CMV IgG level and the likelihood of 
prevalent frailty. Within each tertile, the odds ratio for 
frailty was generally higher with higher CMV IgG levels, 
reaching about 5.18% (95% confidence interval, 0.99-
27.05), for IgG concentrations exceeding 18 IU/mL at the 
third tertile of IL-6 concentration [27]. In addition, the 
data suggested that individuals who were not frail at the 
beginning of the study were more likely to develop 
incident frailty over three years of follow up, although the 
relationship was not statistically significant. Higher 
plasma IL-6 levels were associated with steeper curves in 
this CMV IgG-incident frailty relationship (Figure 1). 
Although it is possible that confounding variables, 
especially socioeconomic status, may have played a non-
trivial role in our study [30], these findings are suggestive 
of a connection between a sustained adaptive response to 
CMV, the activation of an innate immune response, 
characterized by increased production of IL-6, and the 
development of frailty. 
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A. Incident frailty at lower plasma IL-6 concentration 
 
B. Incident frailty at higher plasma IL-6 
concentration 
 
Figure 1. Adjusted cumulative proportion curves of 
incident frailty according to CMV IgG antibody and 
IL-6 concentration. Cumulative proportions of incident 
frailty for older women (N = 299) in 3 contrasting 
categories of CMV IgG antibody concentration 
(seronegative, second quartile [10.17-14.55 IU/mL], and 
fourth quartile [18.17-150 IU/mL]), are shown separately 
at 2 contrasting plasma IL-6 concentrations of 1.6 pg/mL 
(panel A) and 4.8 pg/mL (panel B). Curves were adjusted 
for age, race, high school education, coverage by private 
medical insurance, pack-years of smoking, cardiovascular 
disease (angina, myocardial infarction, congestive heart 
failure, peripheral artery disease, or stroke), diabetes 
mellitus, and plasma IL-6 concentration, with the use of 
Cox proportional hazards model. Interaction between 
CMV antibody and IL-6 concentration was modeled. Age 
was set to 70. Variables other than age, CMV, and IL-6 
were set to 0. The p values indicated in each panel denote 
comparisons between women in the second quartile of 
CMV antibody concentration and CMV seronegative 
women, and between women in the fourth quartile of 
CMV antibody concentration and CMV seronegative 
women, respectively.  
Immunologic markers of frailty 
In further support of a substantial role of the innate 
immune system in the development of frailty, a study 
comparing non-frail to frail or prefrail elder 
populations—this latter defined by satisfying one or two 
of the Fried’s criteria for frailty—detected significantly 
elevated serum levels of IL-6 and of the monocyte-
derived molecule, neopterin, which correlated with the 
severity of the frailty status [20]. Interestingly, neopterin 
plasma levels have also been associated with cognitive 
decline in the elderly, being significantly more elevated 
in subjects with amnestic mild cognitive impairment and 
much more so in patients with Alzheimer’s disease [23]. 
Plasma levels of IL-6 and IFN-γ are also elevated in these 
conditions relative to controls matched by age and other 
variables, both of which are significantly correlated with 
neopterin levels [23]. This is in agreement with the notion 
that IFN-γ, along with other inflammatory factors, is a 
strong inducer of neopterin production in human 
macrophages and dendritic cells [6]. Neopterin is a 
pteridine produced from guanosine trisphosphate (GTP) 
via dihydro-neopterin trisphosphate (NH2PPP), a reaction 
catalyzed by the IFN-γ-induced enzyme, GTP-
cyclohydrolase 1. Accumulation of neopterin is favored 
by the production of reactive oxygen species in IFN-γ-
activated macrophages, which interferes with the 
conversion of NH2PPP to tetrahydropterin, a necessary 
coenzyme for the synthesis of tyrosine and 5-
hydroxytryptophan from phenylalanine and tryptophan, 
respectively. This results in defective production of such 
key neurotransmitters as catecholamines and serotonin, 
responsible in turn for mood, cognitive and motor 
dysregulation. Reduced tryptophan availability also 
results from IFN-γ-mediated activation of the enzyme, 
indoleamine-pyrrole 2,3-dioxygenase (IDO), and the 
ensuing production of kynurenines further contributes to 
neuromotor dysfunction. Notably, IDO activation also 
results in immune suppression and reduced surveillance 
for pathogens and tumors [25]. 
 Taken together, these observations point to 
increased production of IFN-γ from cells of the adaptive 
immune system as a key step in the age-related chronic 
inflammatory process, eventually linked to multiorgan 
dysfunction in the elderly and substantially more so in the 
frail older adult. As an initial approach to functionally 
defining the cellular sources of IFN-γ in this condition, 
we compared the T-cell surface and effector phenotype in 
frail vs. nonfrail octogenarians [8]. Among other markers, 
we looked at the surface expression of CCR5, a receptor 
for the chemokines, CCL3, CCL4 and CCL5, which was 
previously found to be expressed at higher levels in the 
aging host and in T cells is associated with IFN-γ 
production and with a polarized Th1/Tc1 phenotype 
[7,21]. By flow-cytometric determination we 
preliminarily found that circulating T cells that express 
this receptor are an almost exclusive source of IFN-γ 
upon mitogenic stimulation, while production of IL-4 and 
other Th2/Tc2 cytokines is only observed in CCR5
-
 cells 
that express the prostaglandin D2 chemotactic receptor, 
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CD294 [4,7]. In frail donors we detected significantly 
increased numbers of circulating T cells expressing 
CCR5, along with significantly increased numbers of 
CD8
+
 and significantly reduced CD4
+
 T cells [8]. These 
changes were graded across frailty scores, supporting a 
direct correlation with the severity of the clinical picture 
[8]. CCR5
+








reminiscent of the TEMRA clones described in earlier 





 T cells capable of producing IFN-γ—a 
fraction approximating 100% in some cases—were found 
in frail vs. nonfrail donors (G.C.W. and V.C., 
unpublished observations), strongly supporting the idea 
that the prevalence of TEMRA may be considered in itself a 
reliable marker in discriminating frailty from relatively 
healthy senescence. Importantly enough, regardless of 
other conditions, the frequencies of these T-cell clones 
are significantly and markedly more elevated in CMV-
seropositive individuals, further stressing the possible 
contributive role of this pathogen, and the ensuing 
adaptive immune response, in the pathogenesis of frailty 
of older age. 
 
Concluding remarks 
Recent work is shedding new light on the mechanisms 
that account for the immune derailment in frail older 
people and immune senescence in general. Thymic 
atrophy, coupled with chronic antigenic burdens, may 
explain the reduction in T-cell repertoire and the 
enrichment for terminally differentiated, senescent 
clones, which in turn promote chronic inflammation and 
multiorgan deterioration by sustained induction of IL-6 
and other cytokines. Prevalent frailty and the risk for 
frailty are increased in older individuals with high titers 
of CMV IgG and IL-6 plasma concentrations. A graded 
increase in plasma IL-6 can be seen in prefrail and frail 
relative to nonfrail older individuals, and is correlated 
with plasma concentrations of neopterin, a marker of 
IFN-γ-mediated macrophage activation. Our evidence for 





cells is the first to document significant changes in T-cell 
phenotypes in frail older adults. We show that these cells 
mostly express a TEMRA surface phenotype, characterized 
by re-expression of the naïve marker CD45RA and loss 
of the costimulatory marker CD28. This T-cell terminally 
differentiated population expands in response to 
persisting CMV antigen load and may therefore represent 
a link between chronic CMV infection and inflammation 
in frailty. 
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